ABOVE: The new MyHeritage Health+Ancestry test uses a
DNA microarray to detect single-nucleotide polymorphisms.
© ISTOCK.COM, DETART21
When MyHeritage’s chief scientific officer Yaniv Erlich announced the launch of the company’s new Health+Ancestry test on Twitter earlier this summer, the feedback wasn’t entirely positive.
The array-based screen offering insights into a customer’s genealogical and health background from a cheek swab is a rival to 23andMe’s service of the same name. It promises risk reports for genetic variants associated with conditions including breast cancer and heart disease, and, unlike 23andMe, provides conversations with a genetic counselor, should the test turn up anything concerning—all for the price of $199 plus shipping.
But, as some Twitter users were quick to point out, the company’s 5,000-word blog post on the product was thin on medical specifics. “Your blog brags that it tests for, ‘hereditary BRCA cancers (for which we support more variants than our major competitor),’” ...
